Drug Trial Radar · NCT07548606
A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
May 11, 2026
Primary completion
Jun 1, 2026
Study completion Jun 18, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to opevesostat in the body when it is given with and without another medicine called itraconazole.
Conditions
- Healthy
Interventions
OpevesostatDrug
Administered via oral film-coated tablet
PrednisoneDrug
Administered via oral tablet
Fludrocortisone acetateDrug
Administered via oral tablet
ItraconazoleDrug
Administered via oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration versus time curve from 0 to infinity after single dosing (AUC0-inf) of opevesostatTime frame: Predose, and at designated timepoints up to 144 hours post-dose
- Area under the concentration versus time curve from 0 to last quantifiable sample (AUC0-last) of opevesostatTime frame: Predose, and at designated timepoints up to 144 hours post-dose
- Maximum concentration (Cmax) of opevesostatTime frame: Predose, and at designated timepoints up to 144 hours post-dose
- Time to Maximum concentration (Tmax) of opevesostatTime frame: Predose, and at designated timepoints up to 144 hours post-dose
- Apparent terminal half-life (t1/2) of opevesostatTime frame: Predose, and at designated timepoints up to 144 hours post-dose
- Apparent Clearance (CL/F) of opevesostatTime frame: Predose, and at designated timepoints up to 144 hours post-dose
- Apparent volume of distribution during terminal phase (Vz/F) of opevesostatTime frame: Predose, and at designated timepoints up to 144 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion, Inc. ( Site 0001)
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.